Is KIT an Important Therapeutic Target in Small Cell Lung Cancer?

Clinical Cancer Research

Volumn 9, Issue 16 I, 2003, Pages 5825-5828

  Heinrich, Michael C ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; KIT KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG;

CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; LUNG SMALL CELL CANCER; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 0347364770     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (26)

1. Laskin, J., Sandler, A., and Johnson, D. H. An advance in small-cell lung cancer treatment - more or less. J. Natl. Cancer Inst. (Bethesda), 95: 1099-1101, 2003.
2. Johnson, B. E., Fischer, T., Fischer, B., Dunlop, D., Rischin, D., Silberman, S., Kowalski, M. O., Sayles, D., Dimitrijevic, S., Fletcher, C., Hornick, J., Salgia, R., and Le Chevalier, T. Phase II study of imatinib in patients with small cell lung cancer. Clinical Cancer Res., 9: 5880-5887, 2003.
3. Heinrich, M. C., Blanke, C. D., Druker, B. J., and Corless, C. L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT positive malignancies. J. Clin. Oncol., 20: 1692-1703, 2002.
4. Heinrich, M. C., Rubin, B. P., Longley, B. J., and Fletcher, J. A. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum. Pathol., 33: 486-495, 2002.
5. Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., Cross, N. C., Tefferi, A., Malone, J., Alam, R., Schrier, S. L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S. E., Stone, R., and Gilliland, D. G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med., 348: 1201-1214, 2003.
6. Lux, M. L., Rubin, B. P., Biase, T. L., Chen, C. J., Maclure, T., Demetri, G., Xiao, S., Singer, S., Fletcher, C. D. M., and Fletcher, J. A. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol., 156: 791-795, 2000.
7. Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D., Fletcher, J. A., and Demetri, G. D. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 20: 5054-5058, 2001.
8. Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D., and Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 347: 472-480, 2002.
9. van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., van Glabbeke, M., Silberman, S., and Nielsen, O. S. European Organisation for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet, 358: 1421-1423, 2001.
10. Rubin, B. P., Singer, S., Tsao, C., Duensing, A., Lux, M. L., Ruiz, R., Hibbard, M. K., Chen, C. J., Xiao, S., Tuveson, D. A., Demetri, G. D., Fletcher, C. D. M., and Fletcher, J. A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res., 61: 8118-8121, 2001.
11. Corless, C., Heinrich, M., Dimitrijevic, S., Dirnhofer, S., Nikolova, Z., and Fletcher, J. A. Correlation of imatinib response with activation of KIT and PDGF receptors in a variety of cancers: results of the CSTIB2225 trial. Proc. Am. Soc. Clin. Oncol., 2003: 195-195, 2003.
12. Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C. J., Van den Abbeele, A. D., Druker, B. J., Kiese, B., Eisenberg, B., Roberts, P. J., Singer, S., Fletcher, C. D. M., Silberman, S., Dimitrijevic, S., and Fletcher, J. A. Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol., in press, 2003.
13. Ma, Y., Zeng, S., Metcalfe, D. D., Akin, C., Dimitrijevic, S., Butterfield, J. H., McMahon, G., and Longley, B. J. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood, 99: 1741-1744, 2002.
14. Sekido, Y., Obata, Y., Ueda, R., Hida, T., Suyama, M., Shimokata, K., Ariyoshi, Y., and Takahashi, T. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res., 51: 2416-2419, 1991.
15. Rygaard, K., Nakamura, T., and Spang-Thomsen, M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br. J. Cancer, 67: 37-46, 1993.
16. Hida, T., Ueda, R., Sekido, Y., Hibi, K., Matsuda, R., Ariyoshi, Y., Sugiura, T., Takahashi, T., and Takahashi, T. Ectopic expression of c-kit in small-cell lung cancer. Int. J. Cancer Suppl., 8: 108-109, 1994.
17. Burger, H., den Bakker, M. A., Stoter, G., Verweij, J., and Nooter, K. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur. J. Cancer, 39: 793-799, 2003.
18. Micke, P., Basrai, M., Faldum, A., Bittinger, F., Ronnstrand, L., Blaukat, A., Beeh, K. M., Oesch, F., Fischer, B., Buhl, R., and Hengstler, J. G. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin. Cancer Res., 9: 188-194, 2003.
19. Naeem, M., Dahiya, M., Clark, J. I., Creech, S. D., and Alkan, S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum. Pathol., 33: 1182-1187, 2002.
20. Potti, A., Moazzam, N., Ramar, K., Hanekom, D. S., Kargas, S., and Koch, M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann. Oncol, 14: 894-897, 2003.
21. Rossi, G., Cavazza, A., Marchioni, A., Migaldi, M., Bavieri, M., Facciolongo, N., Petruzzelli, S., Longo, L., Tamberi, S., and Crino, L. KIT expression in small cell carcinomas of the lung: effects of chemotherapy. Mod. Pathol., 16: 1041-1047, 2003.
22. Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N. K., and Cherrington, J. M. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther., 2: 471-478, 2003.
23. Krystal, G. W., DeBerry, C. S., Linnekin, D., and Litz, J. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Cancer Res., 58: 4660-4666, 1998.
24. Krystal, G. W., Honsawek, S., Litz, J., and Buchdunger, E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res., 6: 3319-3326, 2000.
25. Krystal, G. W., Honsawek, S., Kiewlich, D., Liang, C., Vasile, S., Sun, L., McMahon, G., and Lipson, K. E. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res., 61: 3660-3668, 2001.
26. Wang, W. L., Healy, M. E., Sattler, M., Verma, S., Lin. J., Maulik, G., Stiles, C. D., Griffin, J. D., Johnson, B. E., and Salgia, R. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene, 19: 3521-3528, 2000.